AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16182827 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine‐microemulsion (ME) (initial daily oral dose 7 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (1.25 mg/kg for 4 days)
Number of subjects: 103
Study 12559940 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (a direct thrombin inhibitor)
Number of subjects: 320
Study 12559940 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 320
Study 12559940 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibrinogen level (pre-treatment top tertile)
Number of subjects: 320
Study 12559940 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-reactive protein level
Number of subjects: 320
Study 10379283 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional resin crowns (n = 25)
Number of subjects: 55
Study 10379283 — intervention group
Group type: COMPARATOR
Intervention: Healing abutments (n = 38)
Number of subjects: 55
Study 10379283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 8919900 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS)
Number of subjects: 263
Study 8919900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 263
Study 1832982 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐human ANF (hANF)
Number of subjects: 20
Study 1832982 — intervention group
Group type: COMPARATOR
Intervention: vehicle alone
Number of subjects: 20
Study 7166045 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand stimulation
Number of subjects: 0
Study 7166045 — intervention group
Group type: COMPARATOR
Intervention: Left hand stimulation
Number of subjects: 0
Study 31182135 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean arterial blood pressure target (77 mm Hg)
Number of subjects: 60
Study 31182135 — intervention group
Group type: COMPARATOR
Intervention: Low mean arterial blood pressure target (63 mm Hg)
Number of subjects: 60
Study 29255272 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg every other day, once a morning
Number of subjects: 88
Study 29255272 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (control)
Number of subjects: 88
Study 29255272 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 88
Study 25475774 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal presentation of postoperative instructions
Number of subjects: 84
Study 25475774 — intervention group
Group type: EXPERIMENTAL
Intervention: Written presentation of postoperative instructions
Number of subjects: 84
Study 25475774 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of postoperative instructions with additional information
Number of subjects: 84
Study 25475774 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety scores
Number of subjects: 84
Study 25475774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociocultural level
Number of subjects: 84
Study 23701115 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV) using dexmedetomidine (4 μg∙kg(‐1)) and topical lidocaine (3‐5 mg∙kg(‐1))
Number of subjects: 80
Study 23701115 — intervention group
Group type: COMPARATOR
Intervention: Manual jet ventilation (MJV) with fentanyl (2 μg∙kg(‐1)), propofol (3‐5 mg∙kg(‐1)), and succinylcholine (1 mg∙kg(‐1))
Number of subjects: 80
Study 21153657 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (n = 31)
Number of subjects: 63
Study 21153657 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (n = 32)
Number of subjects: 63
Study 19214115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm + gel + condoms
Number of subjects: 2429
Study 16749408 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS strategy (sputum eosinophils reduction)
Number of subjects: 55
Study 16749408 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy (based on symptoms and lung function)
Number of subjects: 55
Study 16749408 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS strategy
Number of subjects: 55
Study 15328781 — intervention group
Group type: COMPARATOR
Intervention: Yaw rotation and brief head roll to 35 +/- 2 degrees
Number of subjects: 16
Study 11436970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus immunotherapy (IT) in tablets
Number of subjects: 51
Study 11436970 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (Control)
Number of subjects: 51
Study 9132703 — intervention group
Group type: EXPERIMENTAL
Intervention: Jokes condition (computer presented jokes first)
Number of subjects: 40
Study 9132703 — intervention group
Group type: COMPARATOR
Intervention: Problems condition (computer presented problems first)
Number of subjects: 40
Study 9132703 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-anxious group
Number of subjects: 40
Study 9132703 — intervention group
Group type: COMPARATOR
Intervention: Computer-nonanxious group
Number of subjects: 40
Study 8290411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) + Amiloride (2.5 mg)
Number of subjects: 41
Study 8290411 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg) + Triamterene (50 mg)
Number of subjects: 41
Study 3708884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 3708884 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal diathermy
Number of subjects: 0
Study 30550209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with nasal corticosteroids (budesonide) and nasal antihistamine (azelastine) for 8 weeks
Number of subjects: 120
Study 30550209 — intervention group
Group type: COMPARATOR
Intervention: Budesonide alone for 8 weeks
Number of subjects: 120
Study 30550209 — intervention group
Group type: COMPARATOR
Intervention: Azelastine alone for 8 weeks
Number of subjects: 120
Study 27138024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) 400/12 μg
Number of subjects: 30
Study 27138024 — intervention group
Group type: COMPARATOR
Intervention: Aclidinium bromide 400 μg
Number of subjects: 30
Study 27138024 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate 12 μg
Number of subjects: 30
Study 27138024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate FDC
Number of subjects: 30
Study 25137221 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min/day walking prescription
Number of subjects: 55
Study 25137221 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min/day walking prescription
Number of subjects: 55
Study 25137221 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 min/day walking prescription
Number of subjects: 55
Study 22568858 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 338
Study 22568858 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser vaporization
Number of subjects: 338
Study 22568858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LEEP and CO2 laser vaporization
Number of subjects: 338
Study 20524104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 66
Study 20524104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18212331 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional goal to discredit a threatening message
Number of subjects: 0
Study 18212331 — intervention group
Group type: COMPARATOR
Intervention: Nonthreatening message
Number of subjects: 0
Study 18212331 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy goal introduced
Number of subjects: 0
Study 18212331 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing directional goal or adding accuracy goal
Number of subjects: 0
Study 16328375 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (GAL)
Number of subjects: 149
Study 16328375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 12599088 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine plus nelfinavir or nevirapine
Number of subjects: 127
Study 11515628 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxipide at concentrations of 10-6 to 10-4 M
Number of subjects: 0
Study 11515628 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxipide
Number of subjects: 0
Study 9160413 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms
Number of subjects: 16
Study 9160413 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms
Number of subjects: 16
Study 9160413 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 16
Study 9160413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1602034 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole, 250 mg 3 x a day for 1 week
Number of subjects: 33
Study 1602034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (positive-control)
Number of subjects: 33
Study 1602034 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 33
Study 3912193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin with Amoxicillin
Number of subjects: 14
Study 3912193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin with Ampicillin
Number of subjects: 14
Study 3912193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin with Bacampicillin
Number of subjects: 14
Study 3912193 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 14
Study 3912193 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 14
Study 3912193 — intervention group
Group type: COMPARATOR
Intervention: Bacampicillin
Number of subjects: 14
Study 29395502 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75mg/m2 every 3 weeks for six cycles (Arm A)
Number of subjects: 459
Study 29395502 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (Arm B)
Number of subjects: 459
Study 29395502 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (Arm A)
Number of subjects: 459
Study 27521808 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic public reporting
Number of subjects: 0
Study 27521808 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (smart phone-based application)
Number of subjects: 0
Study 25906700 — intervention group
Group type: EXPERIMENTAL
Intervention: MOM intervention (office-based written and verbal targeted depression education and motivational messages, plus a semistructured telephone booster 2 days later)
Number of subjects: 104
Study 25906700 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (nontargeted written and verbal messages, plus an attention control telephone survey 2 days later)
Number of subjects: 104
Study 22944095 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 200
Study 22944095 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 200
Study 22944095 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 200
Study 20472815 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (mean treatment duration of 25.6 months)
Number of subjects: 3806
Study 20472815 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3806
Study 20472815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3806
Study 18055274 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention for physical activity and dietary change (18 calls over 12 months)
Number of subjects: 434
Study 18055274 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 434
Study 15705978 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided FNA with real-time RT-PCR
Number of subjects: 87
Study 15705978 — intervention group
Group type: COMPARATOR
Intervention: Normal control FNA specimens from patients without cancer
Number of subjects: 87
Study 12915698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day)
Number of subjects: 30
Study 12915698 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (control group)
Number of subjects: 30
Study 12915698 — intervention group
Group type: COMPARATOR
Intervention: Buformine treatment (n=10)
Number of subjects: 30
Study 10591092 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cardiac complications (major and minor)
Number of subjects: 248
Study 10591092 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cardiac complications
Number of subjects: 248
Study 10591092 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diuretics
Number of subjects: 248
Study 10591092 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased time during cross-clamping
Number of subjects: 248
Study 8713688 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg) +/− Indapamide (2.5 mg)
Number of subjects: 60
Study 8713688 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 60
Study 1714021 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 144
Study 1714021 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 144
Study 1714021 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 144
Study 1714021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 7100360 — intervention group
Group type: EXPERIMENTAL
Intervention: High feedback ultrasound (monitor screen visible, shown fetal size, shape, and movement)
Number of subjects: 129
Study 7100360 — intervention group
Group type: COMPARATOR
Intervention: Low feedback ultrasound (screen not seen, specific verbal feedback denied)
Number of subjects: 129
Study 30804274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) for 12 months
Number of subjects: 0
Study 30804274 — intervention group
Group type: COMPARATOR
Intervention: Oral steroids for 6 months
Number of subjects: 0
Study 29069003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 250 mL 20% mannitol and 1 L 0.9% saline orally at 05:00 hours on the day of the procedure.
Number of subjects: 180
Study 29069003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Same preparation as Group A, taken at 20:00 on the day before, and at 05:00 on the day of CE; in addition, 20 mL oral simethicone taken 30 minutes before CE.
Number of subjects: 180
Study 29069003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Identical to Group B, except patients fasted for 3 days and took 3 g senna orally 3 times daily before CE.
Number of subjects: 180
Study 26220784 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Decision Aid
Number of subjects: 155
Study 26220784 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD Decision Aid
Number of subjects: 155
Study 24846362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 24846362 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 22014309 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed personalized feedback regarding alcohol consumption
Number of subjects: 244
Study 22014309 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control group)
Number of subjects: 244
Study 19506821 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS-optimized plans
Number of subjects: 10
Study 17062760 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose bexarotene (400 mg/m2)
Number of subjects: 6
Study 17062760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15313870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen blocker cream applied 4 times daily for 9 days
Number of subjects: 91
Study 15313870 — intervention group
Group type: COMPARATOR
Intervention: Carboxymethylcellulose in gel (placebo) applied 4 times daily for 9 days
Number of subjects: 91
Study 11772856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant intervention delivered by trained community workers
Number of subjects: 32
Study 11772856 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 32
Study 11772856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant intervention
Number of subjects: 32
Study 11181682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral docetaxel 75 mg/m(2) with CsA 15 mg/kg
Number of subjects: 14
Study 11181682 — intervention group
Group type: COMPARATOR
Intervention: Oral docetaxel 75 mg/m(2) without CsA
Number of subjects: 14
Study 11181682 — intervention group
Group type: COMPARATOR
Intervention: Intravenous docetaxel 100 mg/m(2)
Number of subjects: 14
Study 9037321 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment (fosinopril)
Number of subjects: 96
Study 8316680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 1.25 mg/kg/day
Number of subjects: 3
Study 8316680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 2.5 mg/kg/day
Number of subjects: 3
Study 8316680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine plus visual screening
Number of subjects: 3
Study 8316680 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual screening alone
Number of subjects: 3
Study 8316680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 3
Study 3528988 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (n = 9)
Number of subjects: 18
Study 3528988 — intervention group
Group type: COMPARATOR
Intervention: Morphine (n = 9)
Number of subjects: 18
Study 3528988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Methadone and Morphine
Number of subjects: 18
Study 31216898 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted depression intervention
Number of subjects: 0
Study 31216898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31612329 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative S-1 plus oxaliplatin
Number of subjects: 0
Study 31612329 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant chemotherapy
Number of subjects: 0
Study 31612329 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of immune checkpoint inhibitors to cytotoxic chemotherapy
Number of subjects: 0
Study 30167814 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID3
Number of subjects: 47
Study 30167814 — intervention group
Group type: EXPERIMENTAL
Intervention: PsAID9
Number of subjects: 47
Study 30167814 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-arthritis
Number of subjects: 47
Study 27663039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar diet (low-sodium [1,500mg/d], low-protein [0.8g per kilogram of body weight]) and adjusted water intake to achieve urine osmolality ≤ 280mOsm/kg water
Number of subjects: 34
Study 27663039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 27663039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar diet and adjusted water intake
Number of subjects: 34
Study 24994482 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30
Study 24994482 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 21311506 — intervention group
Group type: EXPERIMENTAL
Intervention: SBWL+TECH
Number of subjects: 51
Study 21311506 — intervention group
Group type: EXPERIMENTAL
Intervention: SBWL
Number of subjects: 51
Study 21311506 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH
Number of subjects: 51
Study 21311506 — intervention group
Group type: COMPARATOR
Intervention: Retention rates
Number of subjects: 51
Study 21111986 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEi)
Number of subjects: 4291
Study 21111986 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 4291
Study 21111986 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4291
Study 18688284 — intervention group
Group type: EXPERIMENTAL
Intervention: AEB071 (PKC inhibitor), administered as single and multiple ascending oral doses to patients with psoriasis.
Number of subjects: 0
Study 18688284 — intervention group
Group type: EXPERIMENTAL
Intervention: AEB071 (PKC inhibitor), administered as single doses to healthy volunteers.
Number of subjects: 0
Study 18688284 — intervention group
Group type: EXPERIMENTAL
Intervention: AEB071 (PKC inhibitor), administered to patients with psoriasis.
Number of subjects: 0
Study 15972028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing-induced increases in heart rate up to 150 bpm
Number of subjects: 18
Study 12872392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu Granule (FYG) in addition to conventional chemotherapy
Number of subjects: 55
Study 12872392 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy alone
Number of subjects: 55
Study 10344610 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Number of subjects: 28
Study 10344610 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of amphotericin B per liter of sterile water as continuous irrigation for 72 hours at the rate of 42 mL/hr
Number of subjects: 28
Study 8596486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (12 weeks, three times per week)
Number of subjects: 18
Study 8596486 — intervention group
Group type: COMPARATOR
Intervention: Weight training (12 weeks, three times per week)
Number of subjects: 18
Study 1722769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin treatment (15 mg by continuous infusion two times a week during 5 weeks)
Number of subjects: 55
Study 1722769 — intervention group
Group type: COMPARATOR
Intervention: Classical radiation treatment with telecobalt‐therapy 50 Gy/25 fractions plus 32 Gy/4 fractions (Cathetron)
Number of subjects: 55
Study 31854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (individualized nutritional treatment)
Number of subjects: 128
Study 31854054 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 128
Study 31139911 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who visited 3 different physicians before surgery (Group 1)
Number of subjects: 100